Cortexyme (NASDAQ:CRTX) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.06), MarketWatch Earnings reports.
NASDAQ CRTX opened at $40.87 on Friday. The company’s 50-day moving average price is $49.89 and its 200-day moving average price is $37.87. Cortexyme has a 12 month low of $19.35 and a 12 month high of $73.84.
A number of equities research analysts recently issued reports on the stock. BidaskClub downgraded shares of Cortexyme from a “buy” rating to a “hold” rating in a research note on Tuesday, March 10th. Zacks Investment Research cut shares of Cortexyme from a “buy” rating to a “hold” rating in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $40.00.
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.
Featured Article: How big is the FinTech market?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.